Allogene Therapeutics (ALLO) Depreciation & Amortization (CF) (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 7.42% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $12.2 million (down 7.68% YoY), and the FY2025 full-year result was $12.4 million, down 9.08% from the prior year.
• Depreciation & Amortization (CF) eased to $2.9 million in Q1 2026, from $3.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.9 million in Q3 2022 to a low of $2.9 million in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.5 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Peak annual rise in Depreciation & Amortization (CF) reached 92.49% in 2022, while the deepest fall reached 27.68% in 2022.
• Tracing ALLO's Depreciation & Amortization (CF) over 5 years: stood at $3.1 million in 2022, then grew by 13.33% to $3.5 million in 2023, then dropped by 7.02% to $3.2 million in 2024, then dropped by 4.18% to $3.1 million in 2025, then dropped by 7.39% to $2.9 million in 2026.
• Business Quant data shows ALLO's Depreciation & Amortization (CF) at $2.9 million in Q1 2026, $3.1 million in Q4 2025, and $3.1 million in Q3 2025.